Home / Transcripts / BillionToOne, Inc. (BLLN) · August 5, 2026

BillionToOne, Inc. (BLLN) Earnings Call Transcript

August 5, 2026

NASDAQ US Health Care Health Care Providers and Services earnings 51 min

Earnings Call Speaker Segments

Executive executive
#1

Hello, everyone, and welcome to today's call. Joining me from BillionToOne are our Co-founder and Chief Executive Officer, Oguzhan Atay, along with our Chief Financial Officer, Ross Taylor. The company released its results for the quarter that closed on June 30, 2026 earlier today. That press release is available on BillionToOne's website. Ahead of diving in, we want to remind you that statements made on this call may be forward-looking under Federal Securities Laws. Such statements, which concern future events, might address our financial outlook and performance, market size, our products and services, reimbursement coverage, future clinical performance, and comparable matters. Please keep in mind that what we're sharing reflects how we see things right now, and the outcomes we actually achieve might end up looking quite different from anything suggested or stated in forward-looking remarks. You can find a discussion of the risk factors that might lead to different results in the documents we file with the SEC — that includes the annual report on Form 10-K we submitted earlier, the quarterly report on Form 10-Q that we'll submit once this call wraps up, and the current report on Form 8-K that went in today. Anything forward-looking we say on this call speaks only as of today, August 5, 2026. If someone replays or goes back over this call after today, what was said here might no longer be up to date or correct. Any duty to revise forward-looking statements in public—whether due to fresh data, upcoming occurrences, or other reasons—is rejected by BillionToOne, unless the law mandates it. Having said that, Oguzhan will now take over the call.

Oguzhan Atay executive
#2

Good afternoon, everyone, and thanks for being on our second quarter 2026 earnings call. First, I want to express appreciation to our patients and providers, who place their trust in us for extremely important healthcare decisions, and to our employees, who bring tremendous effort each day to build and deliver superior tests that enhance patient care and eliminate the fear of the unknown. Before getting into quarterly results, let me remind you of the four pillars that I believe set us apart as a different category of molecular diagnostics company. Pillar one is our revolutionary technology platform, powered by our patented QCT, Quantitative Counting Template technology. Thanks to next-generation sequencing, we achieve sensitivity and precision down to a single molecule. That capability has allowed us to build distinctive products that define their categories in prenatal and oncology. Then, in our second pillar, those offerings helped us grow rapidly—going from nothing to a $438 million annualized revenue run rate across six years. We believe we're still early, perhaps below 1% of the potential, because we think cell-free DNA testing for prenatal and oncology could exceed an estimated $100 billion in the U.S. by itself. Now, the third pillar is really important. Because our technology is unique, it gives us a better signal-to-noise advantage, and we've stayed relentlessly focused on cutting COGS and growing ASP, we've been able to combine fast growth with a gross margin profile that's superior. Margins are now above 70%, and there's still a lot of room to expand by growing ASP and reducing COGS per test. Last, this superior gross margin, along with a culture of fiscal discipline and efficient operations that use AI, has gotten us to GAAP profitability. We've done this at a much smaller scale than our public competitors, and our accumulated deficit is roughly 10% of theirs. To wrap up, our long-term objective hasn't changed and we're still on course to reach it: creating a generational company that defines its category, reshaping molecular diagnostics and how care is delivered for millions of patients, and earning a place in the S&P 500. Across every pillar, Q2 was solid — another period marked by substantial growth, superb margins, and positive operating income along with cash flow. I'll walk through each pillar more thoroughly. In short, we're bringing new offerings to market in both prenatal and oncology, plus we've released data that we think will back MolDX coverage for Northstar Response. Our fast expansion carried on, with test volume climbing 35% compared to a year earlier and revenue rising 64% year-over-year. We kept our gross margin at a strong level — 70.5% for the quarter, up five percentage points from the same period last year. Even though cost of goods sold per test went up as our test mix tilted more toward oncology, our gross margins have held quite steady over the last several quarters. And on top of that, even as we increased what we spent on commercial scale and R&D, we still maintained a healthy level of profitability: GAAP operating income of $5.5 million, a 5% operating margin, and an adjusted EBITDA margin of 15%, which is impressive. As a result, we ended the quarter with cash growing to $549 million. Now I'll take you through the quarter, pillar by pillar. Let's start with the first pillar — our platform and products. Turning to prenatal: Unity Confirm has seen robust uptake ever since its May 28 launch. Keep in mind that this assay is the only non-invasive confirmation test of its kind, and it's designed for pregnancies considered high-risk. The way it works: it grabs intact fetal cells circulating in the blood and sequences them, which yields a fetal fraction of 100% — putting it in an entirely separate category from the usual cell-free DNA testing. Our go-to-market approach positioned it as a targeted follow-on for high-risk pregnancies that our Unity aneuploidy screen had flagged. When a patient either cannot go through invasive diagnostic testing or chooses not to, Unity Confirm provides a non-invasive option that simply did not exist before, and it arrives at a sensitive time when choices may feel limited. Unity Confirm has gotten off to a great start. Providers already are using it for more than half of their high-risk Unity aneuploidy patients who qualify. In addition, we continue to enroll patients in what we view as the largest prospective study ever conducted using circulating fetal cells. At the same time, Unity Confirm is opening doors even at no-see health systems, which as a rule allow no sales representatives whatsoever. We expect a meaningful effect on the Unity franchise over the long term, especially as forthcoming readouts from that study become available and it is recognized as the new standard for non-invasive testing. Our prenatal product engine didn't pause there; on August 17, we're taking our UNITY Fetal Risk Screen to 130 genes — the biggest panel available that doesn't depend on partner testing, far outpacing what competitors offer. Roughly 50% of providers overall favor large panels for these inherited conditions. We think this expansion will significantly grow our serviceable market. The panel covers prevalent actionable conditions chosen from ACOG, ACMG, and RAST guidelines, and it cements Unity's standing as the leader in cell-free DNA testing for recessive conditions. Moving to oncology, we produced meaningful new clinical evidence during the quarter. A peer-reviewed paper came out on June 24 in the Journal of Liquid Biopsy, and it validated Northstar Response for tracking immunotherapy as well as immuno combination therapy. That research covered 142 patients, more than 750 samples, two prospective cohorts, and 12 tumor types. Worse survival was strongly predicted by molecular progression — clearly superior to imaging on its own, and combining the two performed even better. The test also separated radiographically stable patients into actual responders versus non-responders, demonstrating added benefit past standard of care imaging. We intend this publication to support our push to obtain MolDX Medicare coverage for Northstar Response in the IO and IO combination therapy settings. Because response makes up nearly 66% of the oncology test volume we handle, this coverage continues to be among our biggest catalysts, and we still expect it before this year is over. On the topic of catalysts, we are likewise on schedule to launch our highly sensitive tumor-naive MRD by year-end; worth noting is that QC failure occurs in under 1% of our liquid biopsy assays, whereas assays needing tissue sequencing typically see 15%-30%. In addition, on September 1st we are making two significant updates to Northstar Select. First, the panel grows to 102 genes so it covers recent and upcoming FDA therapy approvals, among them highly sensitive detection of MTAP copy number loss. About 15% of all cancer patients have MTAP loss, and it is the target of multiple promising ongoing clinical trials. As we said before, copy number losses prove extremely hard to spot in liquid biopsy, an issue our technology solves. Second, we are introducing Northstar Origin, a tissue of origin add-on that we believe will provide best-in-class performance. With call rates higher than any comparable offering. Around 3% of patients show up with cancer of unknown primary, leaving them short of effective therapy options. What's more, in community oncology settings the share of patients with uncertain diagnoses can hit 10%, particularly when detailed pathology workups are unavailable to them.

Oguzhan Atay executive
#3

Northstar Origin works by counting molecules through methylation using QCT technology. When identifying where a tissue came from, it reaches 91% for top 3 and 86% for top 1 accuracy, and that assists these patients in getting a diagnosis along with effective treatment. Turning to pillar number two, scalable rapid growth: in Q2, test volume overall climbed 35% compared with the same period last year, hitting approximately 196,000 tests, which is about 8,000 more than the previous quarter. For prenatal, our growth landed right where we anticipated, while for oncology it came in above our expectations. A key point is that we added around 70 sales reps in the first half of the year, moving faster than planned, because our hiring pipeline has been so strong. Our short-term sales productivity took a bit of a hit because of how quickly we brought people on board. Even so, we expect that once these reps are fully up to speed and get into the health systems — especially as those systems also complete EMR integration — the hiring will drive faster growth as we close out this year and head into the early months of next year. Turning to EMR integrations, we went live on the Epic Aura platform in less than five months, which is the fastest any laboratory has ever launched on Epic Aura, and we finished our first Aura health system integration only two weeks from kickoff to the first test order. A major obstacle to health system adoption is eliminated by Epic Aura. Bringing health systems on board is still going to be a gradual process, because the IT group at every health system has to work our integration into a roadmap that typically sits two to four quarters ahead; we anticipate a meaningful impact as we move into next year. Because our oncology tests are scaling so fast, we also signed a lease for a dedicated oncology production lab of 62,000 square feet, located directly across from our existing prenatal production lab in Union City, California. Design and build-out are in progress, with production expected by the end of 2027, and over time the facility is designed to support oncology capacity of roughly 5,000 tests per day. Turning to each product line, prenatal and oncology both contributed meaningfully to our growth. During Q2, prenatal brought in $95.8 million, a 56% increase compared with the same period last year, fueled by solid commercial execution and higher ASPs. Oncology grew even more rapidly, with revenue up 176% year-over-year to $13.7 million, nearly tripling, which works out to an annualized run rate of about $55 million. The revenue results we posted this quarter highlight the extraordinary growth achieved over the past six years, climbing from roughly zero to $438 million in annualized run rate. For the quarter, total revenue reached $109.4 million, a 64% year-over-year gain, powered by strong increases in both tests delivered, which rose 35%, and ASP, which rose 21%. I'd point out that although reported revenue was up only modestly on a sequential basis, that figure understates the momentum beneath the surface. When we leave out true-up revenue, our total revenue was up 8% from one quarter to the next. That kind of steady growth remains a key element of our pillars. Now on to pillar three, beginning with our ASPs. On a year-over-year basis, overall ASP rose 21%, reaching $551 for each test. From the prior quarter, ASP was down by roughly $20. That drop is purely about the timing of true-ups. The true-up in Q1 amounted to $49 per test, whereas in Q2 it was $14 per test. The key point is that once you remove the true-up impact, ASPs went up $15 between the two quarters. By mutual agreement, we delayed submitting more than $10 million worth of claims in the quarter, since we were waiting on national payers to get our codes loaded in network. That held back cash collections for a while, put a bit of pressure on the ASPs we were able to get, and might have reduced true-up revenue in the quarter. Once those claims move through processing and get paid, we expect things to resolve themselves across the back half of the year. The signal that matters more is this: setting true-up aside, overall ASP continued to rise quarter over quarter, driven by a record count of payer contracts signed in the quarter. Beyond fueling ASP growth, we have stayed true to our operating philosophy of continuous improvement aimed at bringing down COGS per test. In Q2, overall COGS per test reached $161, compared with $152 in Q1 and $156 one year earlier, and the rise stemmed from our volume mix shifting toward oncology. Beneath that mix effect, our operational discipline remains fully intact. Prenatal COGS was roughly flat on a sequential basis, even with the Unity Confirm launch, and in oncology we delivered COGS reductions exceeding 10% from quarter to quarter. Since oncology keeps expanding faster than prenatal, we anticipate overall COGS per test will climb steadily as time goes on. Consequently, our gross margin stayed at 70.5% in Q2, roughly five percentage points above the prior-year figure, thanks to higher ASPs, even while our earlier-stage, lower-margin oncology tests expanded by more than 100% over that same stretch. What's key is that the minor quarter-over-quarter swings in gross margin across the last four quarters stem almost completely from differences in the quarterly true-up. With true-up excluded, our gross margin has stayed remarkably steady at roughly 70%, even amid the substantial mix shift toward oncology. We plan to keep lifting ASP in prenatal and oncology, while also reducing COGS in oncology, so we expect to maintain robust gross margins of 70% or more, even as oncology becomes a much bigger share of our total business. With that, I'll pass things to Ross, who will review our financial results and guidance before I close.

Ross Taylor executive
#4

Thank you, Oguzhan. As Oguzhan pointed out, during the second quarter of 2026, our results were strong, pairing 64% growth in revenue year over year with a 5% GAAP operating margin and a 15% adjusted EBITDA margin. Revenue for Q2 of 2026 totaled $109.4 million, up from $66.6 million in the same quarter of 2025 — a rise of 64%. In the quarter, both our prenatal and oncology product lines showed robust growth. Prenatal revenues, which include clinical testing plus clinical trial support and other services, rose 56%, reaching $95.8 million in Q2. Oncology revenues climbed 176%, hitting $13.7 million in Q2 of 2026 against Q2 of the prior year. Growth in our overall revenue came mainly from higher test volumes in both prenatal and oncology, along with ongoing year-over-year increases in both our prenatal and oncology ASPs. True-up revenue came to $2.8 million in the second quarter of 2026, versus $9.2 million in the first quarter of 2026 and $2.1 million in the same quarter a year earlier. If you set aside true-up revenue, total revenue was up 8% sequentially from the first quarter of 2026. Gross profit for the second quarter of 2026 reached $77.1 million, up from $43.5 million in the second quarter of 2025, which works out to a gross margin of 70.5% in Q2 of 2026 against 65.3% in last year's second quarter. That gross margin improvement came chiefly from ongoing gains in our overall ASP. Total operating expenses amounted to $71.6 million in the second quarter of 2026, versus $45.1 million in the comparable quarter a year earlier — a 59% increase. Inside total operating expenses, R&D expense came to $17.3 million in the second quarter of 2026, versus $11.8 million in the comparable prior-year quarter. SG&A expense reached $54.3 million in the second quarter of 2026, versus $33.3 million in the comparable prior-year quarter. Operating income was $5.5 million in the second quarter of 2026, against an operating loss of $1.6 million in the second quarter of 2025. Our operating profit margin in Q2 was 5%, versus the 16% operating margin we posted in the first quarter of 2026. A bit more than half of the gap in operating profit relative to Q1 stemmed from the difference in true-up revenue between those two quarters. The rest came from continued investment in our commercial and R&D organizations, plus faster growth in oncology. Adjusted EBITDA in Q2 equated to a 15% margin. Net income available to common shareholders came to $8.1 million, or $0.15 per diluted share, in the second quarter of 2026, versus a net loss of $0.2 million in the same period of 2025. Turning to the cash flow statement for the second quarter, cash flow from operations was $9.1 million, and capital expenditures were $4.0 million; that left us with free cash flow of $5.1 million in the second quarter of 2026; we are well capitalized, with a very healthy balance sheet. At the close of Q2, cash and equivalents totaled $549 million. Our balance sheet, we believe, sets us up well for robust expansion ahead, especially in light of our plan to keep running the company with an eye toward profitability and positive cash flow. Last, I'll give you an update on the guidance we've set for the entire 2026 year. Our outlook for 2026 total revenue stays at $450 million to $465 million, which reflects roughly 48%-52% growth versus the full 2025 year; beyond that, we anticipate operating the business so that it keeps producing profitability in line with what we see now, even as we make substantial ongoing investments. With that, I'll hand the call over to Oguzhan for closing remarks.

Oguzhan Atay executive
#5

Thanks, Ross. To sum up, we're changing healthcare through one molecule at a time and one patient at a time. My confidence, as it always has been, rests not on any one piece, but on how everything we've built compounds. Every product we bring to market strengthens our platform further, from Unity Confirm to the broader fetal risk screen to Northstar Origin, and every study we release adds more evidence of our technology's clinical utility, just as our Northstar Response publication did during this quarter. When it comes to finances, our profile stays the strongest in our sector. This quarter, once more, we showed solid revenue growth, reaching a $438 million annualized run rate. Gross margins stayed above 70%, and we prove that growing quickly need not sacrifice profitability. What drives us is a group of deeply committed, mission-focused people who turn up each day sharing one goal: creating a real difference in the lives of patients. Our aim hasn't changed: to reshape molecular diagnostics, create a company that defines its category, and secure a spot in the S&P 500. We're happy with how far we've come and eager to bring you updates as the year moves along. Thanks. I'll hand it to the operator.

Mark Massaro analyst
#6

Hi there, thanks for letting me ask some questions. To start with, it's clear the true-up figure fell by roughly $6 million between Q2 and Q1. Oguzhan and Ross, I just want to confirm that, excluding true-ups, your prenatal test revenue still grew from one quarter to the next. Am I right about that?

Oguzhan Atay executive
#7

Yes, that's right, Mark. For prenatal ex true-up, both test volumes and ASPs went up, so the combined figure rose considerably too. Ross, would you like to talk through the specific numbers?

Ross Taylor executive
#8

For the actuals.

Oguzhan Atay executive
#9

On the prenatal revenue.

Ross Taylor executive
#10

When it comes to prenatal revenue, Mark, you can basically take it that nearly the whole true-up ties back to prenatal. There's a chart we've got—slide 14 in the deck, I believe—and from it you should be able to put together some fairly solid estimates of what prenatal revenue looks like excluding the true-up. My apologies, I don't actually have those figures sitting in front of me at the moment, and we haven't disclosed that level of detail previously, but on a sequential basis, excluding the true-up, it's up by more than a couple million dollars.

Mark Massaro analyst
#11

I realize you're up against plenty of competition. A lot of other companies are active in this area. You've clearly been gaining share for quite a while. So could you describe what you're observing on the competitive front? And tied to that, here's my final question: it sounds like you sped up the pace of sales rep hiring compared with what you'd planned. I'm just wondering whether some of that increased hiring could be connected to the competitive landscape.

Oguzhan Atay executive
#12

Mark, second quarter volumes came in almost exactly where we anticipated for the quarter. In prenatal, our growth matched what we expected, and in oncology we came in a bit ahead of expectations when it comes to test volume. We weren't hiring because of competition — it's actually because of the ongoing opportunity in front of us, particularly when it comes to health systems. Our approach to running this business is aimed at growth over the medium to long term. There are roughly four factors we think will converge over the coming two to four quarters and truly drive meaningful prenatal growth. Bringing on sales reps is the first, though naturally they need time to be onboarded, become productive, and begin penetrating health systems. Right as we bring these sales reps on, Unity Confirm is creating openings with new health systems. We think additional data readouts arriving over the next two to three quarters will speed that up even more. Third, we finished onboarding onto the Epic Aura platform more quickly than any other lab. Seeing a meaningful impact from that will take two to four quarters. Our execution there is going extremely well. Last, I want to emphasize how important the 130 gene Fetal Risk Screen launch is. It's set to be a major competitive advantage, and its effect will be even larger among health systems that want a portfolio of offerings, these large panels included. We genuinely think these four factors will converge over the next two to four quarters, building a real engine of health system adoption capable of generating substantial volume growth. What we're really focused on in the first half of the year is this: with the hiring pipeline we've managed to build since going public, we've ramped up hiring so that all these reps come aboard and get onboarded at the right moment, ensuring that as these opportunities converge, we're strongly positioned to convert that test volume from health systems.

Mark Massaro analyst
#13

That's quite useful. OK. Appreciate it, everyone.

Dan Arias analyst
#14

Hey, everyone. Thanks for taking the questions. Oguzhan, I believe you touched somewhat on that volume trend. Could you perhaps give us a bit more detail on how it looks sequentially in oncology once the ASP factor is removed? How much did volume rise quarter over quarter as a trajectory? And then, for the back half of the year, how ought we to be thinking about it compared with what you may have been expecting earlier in the year?

Oguzhan Atay executive
#15

Oncology ASPs truly stayed flat from one quarter to the next. We are awaiting and pursuing MolDX coverage of Response. Before that occurs, ASPs in oncology remain quite steady. Looking at the chart Ross mentioned, the true-up for oncology in both quarters was nearly very minimal too. Every bit of the sequential growth you observe stems from test volume gains in oncology. Oncology test volumes are performing very well, even beyond what we had anticipated; that is among the reasons we began building this oncology lab, and I think we are demonstrating that we are prevailing in the market with the products we have, and as we bring in more competitive elements to our oncology offerings, we hold a lot of confidence in the trajectory.

Dan Arias analyst
#16

Would you expect that path to produce quarter-over-quarter volume growth every time? I realize 4Q can behave oddly, yet your comments suggest solid momentum. Without splitting hairs, I just want to know if 2Q to 3Q might rise and then 3Q to 4Q might rise too, so our model reflects reality. Thanks.

Oguzhan Atay executive
#17

Regarding 2Q to 3Q, strong momentum is definitely what we're seeing. Like you said, when it comes to how many providers get added, 3Q to 4Q is usually somewhat of a robust period, but when you look at accessioning days and how test volumes and revenues convert, it's usually somewhat of a compressed period. What we're observing is that our oncology work is moving forward faster than planned.

Dan Arias analyst
#18

Okay, thank you.

Ricki Levitus analyst
#19

Hi, this is Ricki, filling in for Subbu. We appreciate you taking our questions. You provided some detail regarding the Unity Confirm launch and adoption, along with the 50% opt-in for the eligible results. Although we're still in the early days of this launch, do you believe that is already beginning to generate share gains in NIPT?

Oguzhan Atay executive
#20

I believe it is definitely creating opportunities, and it is lowering the inclination for at least a number of accounts to split. I think splitting test volumes across multiple labs is uncommon for prenatal clinics, and Unity Confirm does stop that splitting, I'd say, to a greater degree. I think it will be a long-term driver instead of a much shorter-term driver, especially since many of the remaining opportunities are health systems, and they don't get onboarded within one or two months. Unity Confirm launched on May 28th, and it is already experiencing strong adoption, and it's already getting us through the door at these health systems. These health systems require many other things such as EMR before they are able to switch to another lab; that's why we are really confident that all of these factors are coming together to drive an acceleration of growth, particularly as we look to growth next year.

Ricki Levitus analyst
#21

Understood, that's useful. You also told us about the broader panel for risk screening that covers 130 genes. I'm just curious whether anything has shifted in the way you view the per-test economics for that, whether on the reimbursement side or with COGS. Thanks.

Oguzhan Atay executive
#22

When it comes to the 130 gene panel, we don't anticipate a meaningful economic difference. Nor will it suddenly account for a big share of our test volume, but my sense is that it will open doors for us with certain health systems and other organizations that have a strong preference for a large panel being available. Since this stands alone as the large panel that includes a cell-free DNA option, I believe it will give us a significant edge over competitors.

Noah Kava analyst
#23

Hello, Noah Kava here from Tycho. We appreciate you fielding our questions. I'd like to ask about the Northstar Origin news that came out today. In your view, what share of the patients you serve could realistically be candidates for this? And how do you expect the financials to shake out across the coming 2 quarters?

Oguzhan Atay executive
#24

The economics of the product probably won't shift dramatically because of Northstar Origin. My sense is that it will generate added uptake of what we offer; this topic in particular has come up more and more often in conversations with providers. I believe it's turning into a significant consideration, above all in community oncology environments, where the proportion of cases isn't 3%. When it comes to CUP cases, the genuinely unknown primary situation sits at roughly 3%. For certain oncologists, that alone could be a meaningful factor pushing them toward one platform instead of another. We're additionally observing that within community oncology settings, this challenge exceeds a 3% challenge, particularly given that they lack access to the full range of pathology workups. In that context, as many as 1 in 10 patients may carry an uncertain diagnosis. That genuinely complicates what comes next for those patients. My expectation is that the economics won't be altered, yet it will serve as one more catalyst for uptake, much like what we've observed thus far with our ChIP-sequencing and the PGx offerings we brought to market during the first quarter.

Noah Kava analyst
#25

Thank you. As a second question, a rival of yours mentioned growing resistance from payers regarding prenatal testing, particularly when it comes to carrier screening. I'm wondering whether you can share anything about that, and whether you're encountering similar pushback.

Oguzhan Atay executive
#26

No resistance has shown up on our end, though part of the reason is that we've been, I'd say, quite deliberate regarding our approach to coding within this specific area. For nearly all of our tests, we submit claims with the PLA codes we've secured, instead of depending on the bundled or stacked billing practices that are more typically seen. This is a pattern we've noticed, particularly as certain national payers insist these panels cannot be unbundled and submitted with separate codes. Our PLA code became effective January 2025. The friction that I believe some other prenatal testing companies may be dealing with is simply not an issue for us.

Noah Kava analyst
#27

Thanks.

David Westenberg analyst
#28

Hello, and thanks for fielding my question. What I'd like to ask about is, when you compare this year to last year — actually on slide 14, and I appreciate it, that's quite a bit of information — I believe Ross brought up $4.5 million in sequential revenue. Looking at it year-over-year, it appears to be unchanged. I'm simply somewhat curious. I'm aware that Natera reports seasonality in Q2. I'm aware that historically you folks have stated you haven't observed it, but back then you made up a much smaller share of the market. Do you believe there could be extra seasonality for you in Q2 within non-prenatal testing, and that it might track those very same patterns, with Q3 and Q4 perhaps performing better?

Oguzhan Atay executive
#29

Definitely, fewer patients are being tested within the accounts we already hold. There is, I believe, definitely a modest effect when it comes to seasonality. That seasonality isn't something we model, and even with it we managed to stay ahead of our plan. We didn't want to bring up seasonality in a quarter during which we were able to be at or ahead of what we had modeled absent that seasonality. That is definitely the case. When you examine the count of pregnancies and births, or even the count of tests coming from accounts where you know you're capturing 100% of the test volume, there's a decline in Q2 when it comes to test volume; that seasonality, I believe, is genuine. The effect, I think, is usually fairly modest, but as you noted, once we get bigger, seasonality can certainly have a larger impact. We didn't want to bring it up since we didn't model it that way.

David Westenberg analyst
#30

Let's discuss those reported claims totaling $10 million, I believe, that were sitting with national payers in Q2 and which you held back until your true-ups. Could you walk us through how that works? When those particular claims finally get processed, in what way does that $10 million come through? I simply want to verify — and I think this has always been the situation — that you aren't factoring true-ups into your guidance for the back half, right? My understanding is that's how you've consistently handled it, but I'd just like that confirmed. Thank you. Thanks so much, everyone.

Oguzhan Atay executive
#31

Ross, would you like to address the true-up question, and after that I'll handle the $10 million one?

Ross Taylor executive
#32

Absolutely. Yeah, that's right when it comes to the true-ups and what we've guided. David, in the forward-looking guidance we're giving, we genuinely aren't factoring in any true-ups at all, other than those we've already disclosed.

Oguzhan Atay executive
#33

Regarding that $10 million tied to health claims, part of it does sit inside realized revenue, since ASC 606 requires us to treat it that way, but our approach has been quite cautious. Should all of those back claims get processed and paid, there's significant upside potential. Our preference is to stay conservative here; we still lack full visibility into when, or how much, will eventually be collected on the claims we're holding. That's the reason we're keeping guidance in place until things become clearer.

Casey Woodring analyst
#34

Thanks. I appreciate you taking my questions. I might just ask one. You spent a lot of time discussing the launch on Epic Aura during the quarter and mentioned that your integration happened more quickly than any other lab's. Could there be a situation where full integration is complete before we get into 2027? You mentioned a meaningful impact next year. Is there any way to put a number on what that impact from full integration would be in your base case?

Oguzhan Atay executive
#35

Thank you, Casey. With Epic Aura, our integration is complete. The thing is, even once integration with Epic Aura is fully done, every health system still has tasks remaining to activate its Epic Aura and to ensure orders and test results flow back and forth properly. Usually, the time a lab needs to integrate with every health system on its own, individually, still tends to run, for many labs, six months or more; that's what we've heard in the field. By contrast, our integrations have moved at lightning speed. Our initial integrations took two to four weeks, which is a record even for these one-by-one health system integrations. We're leveraging that to push these health systems to make our integrations a priority and fit that sort of individual integration into their roadmap. It can still be two to four quarters out. The moment we get the green light, we can complete these integrations extremely fast. After they're finished, I believe we'll see meaningful growth in test volume. To give you a sense, once a health system is onboarded, each one can range anywhere from 1 to 3,000 tests per quarter. What tends to happen is that this tends to be a funnel, and the funnel genuinely began around May or June. As we work our way into their roadmaps, I think it will start slowly and then accelerate quite significantly over time. As for how much incremental test volume this will bring, that's very hard to state, because, again, it isn't about our own teams and what they're capable of. It's about how many health systems we can persuade to place our individual integration into their roadmap.

Casey Woodring analyst
#36

Got it, that helps. Then perhaps just one more on gross margin. You posted 70.5% here. How should we think about how that moves once Northstar Response gets reimbursed? Sort of what does the forward trajectory look like there once you can switch that on? Thank you.

Oguzhan Atay executive
#37

Thanks; good question. One way to look at it is that we're truly running the company to balance growth against gross margin and profitability. Even at the point when Northstar Response arrives with the MolDX coverage, we'll be launching MRD at that same time, and we won't be throttling the MRD test volume. What that means is that, as the Northstar Response ASPs rise and as our oncology gross margins go up, we'll have dilutive gross margins coming from that growth we see from MRD. The way we think about it is that if the business performs as planned and modeled, we expect to hold 70% gross margin, no matter the mix or growth of oncology or the lumpiness of the true-up revenue. That's what we've observed over the last four quarters, when gross margin was 70% without true-up each quarter despite the really fast growth we had in oncology. I think we'll keep seeing that, and we'll keep, I think, managing the business to stay above 70% gross margins by raising ASPs across different product lines and cutting COGS, especially in oncology. That said, an unexpected acceleration in oncology business far beyond what we're modeling could even cause gross margins to be temporarily below 70%. What matters here is that each product is designed to deliver 70%-80% gross margin over the long term with scale and appropriate coverage. It's just that, as some of our more mature products get closer to 80% gross margin, we're building and launching new products that become dilutive to gross margin. The balance becomes something in the range of 70% gross margin.

Casey Woodring analyst
#38

Okay, got it. Thanks. And just so we're clear on the scale, each one can run anywhere from 1,000 to 3,000 tests in a given quarter.

Operator operator
#39

No more questions are coming in right now. So that brings today's presentation to a close. Thanks for joining us. You're welcome to disconnect at this point, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete BillionToOne, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to BillionToOne, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.